Rezūm therapy: Outcomes of symptom relief and quality of life in benign prostatic obstruction with three-year followup

Authors

  • Mario Henrique Bitar Siqueira Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada
  • Sagi Shprits Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada
  • Omar Buksh Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada
  • Naeem Bhojani Division of Urology, Centre Hospitalier de l’Université de Montréal (CHUM), Montréal, Canada
  • Bilal Chughtai Plainview Hospital, Smith Institute of Urology, Northwell Health, Syosset, United States
  • Kevin C. Zorn BPH Canada, Prostate Surgical Institute, Montreal, Canada
  • Luca Cindolo Urology Department, Hesperia Hospital, CUrE Group, Modena, Italy
  • Giovanni Ferrari Urology Department, Hesperia Hospital, CUrE Group, Modena, Italy
  • Rosario Calarco Piazza Urology Department, Hesperia Hospital, CUrE Group, Modena, Italy
  • Salvatore Rabito Urology Department, Hesperia Hospital, CUrE Group, Modena, Italy
  • Katherine Lajkosz Department of Biostatistics, University Health Network, Toronto, Ontario, Canada
  • Dean Elterman Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada

DOI:

https://doi.org/10.5489/cuaj.9314

Keywords:

Rezūm Water Vapor Thermal Therapy, lower urinary tract symptoms, benign prostatic hyperplasia, sexual function, minimally invasive surgical therapy, prostate volume, long-term outcomes

Abstract

INTRODUCTION: This study evaluated the long-term efficacy and safety of Rezūm water vapor thermal therapy (WVTT) for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The objective was to assess the durability of symptom relief and sustained LUTS improvement over a three-year followup in a real-world, multicenter cohort.

METHODS: A prospective registry was maintained at two high-volume, international centers for men undergoing Rezūm therapy between April 2019 and October 2024. All participants had baseline clinical data recorded, including BPH history, uroflowmetry parameters (peak flow rate [Qmax] and postvoid residual [PVR]), and validated questionnaires (International Prostate Symptom Score [IPSS], IPSS quality of life [QoL], BPH Impact Index [BPHII], International Index of Erectile Function [IIEF-15], and Male Sexual Health Questionnaire for Ejaculatory Dysfunction [MSHQ-EjD]).

RESULTS: A total of 712 men with at least one year of followup were analyzed. The mean age was 67.2 years (standard deviation [SD] 8.9), and the average baseline prostate volume was 74.1 cc (SD 34.4). Mean IPSS scores improved from 22 at baseline to 9.8 at 36 months. IPSS QoL scores improved from 4.5 to 1.9. Qmax increased from 8.6 ml/s at baseline to 15 ml/s at 24 months and 12.1 ml/s at 36 months. PVR decreased from 134.9 ml to 38.5 ml. There were no significant changes in IIEF or MSHQ-EjD domains.

CONCLUSIONS: Rezūm WVTT provides significant, durable symptom relief and improved urinary function over three years, with preserved sexual function.

Downloads

Download data is not yet available.

Author Biography

Dean Elterman, Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada

Division of Urology/Department of Surgery

Assistant Professor

Downloads

Published

2025-12-15

How to Cite

Henrique Bitar Siqueira, M., Shprits, S., Buksh, O., Bhojani, N., Chughtai, B., Zorn, K. C., … Elterman, D. (2025). Rezūm therapy: Outcomes of symptom relief and quality of life in benign prostatic obstruction with three-year followup. Canadian Urological Association Journal, 20(4), 94–100. https://doi.org/10.5489/cuaj.9314

Issue

Vol. 20 No. 4 (2026): CUAJ April

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.